- A Phase 1 Study with ABBV|CLS|484 Alone and in Combination in ...🔍
- ABBV|CLS|484🔍
- A Phase 1 Study With ABBV|CLS|484 in Subjects With Locally ...🔍
- A Phase 1 Study With ABBV|CLS|484 Alone And In Combination In ...🔍
- Clinical Trial🔍
- First|in|human phase 1 studies of PTPN2/1 inhibitors ABBV|CLS ...🔍
- Advanced Renal Cell Carcinoma Clinical Trials🔍
- Kidney Cancer Clinical Trials🔍
A Phase 1 Study with ABBV|CLS|484 Alone and in Combination in ...
A Phase 1 Study with ABBV-CLS-484 Alone and in Combination in ...
The study will assess the safety, PK, PD, and preliminary efficacy of ABBV-CLS-484 as monotherapy and in combination with a PD-1 targeting agent or with a ...
A Phase 1 Study With ABBV-CLS-484 in Subjects With Locally ...
... combination with a PD-1 targeting agent or with a VEGFR TKI to eligible subjects who have advanced solid tumors. Part 3, ABBV-CLS-484 will be administered alone ...
A Phase 1 Study With ABBV-CLS-484 Alone And In Combination In ...
Grant Details: A Phase 1 Study With ABBV-CLS-484 Alone And In Combination In Subjects With Locally Advanced or Metastatic Tumors.
A Phase 1, Multi-center, Open Label First-in-Human Study With ...
The purpose of this study is to see how safe and effective ABBV-CLS-579 is when used alone or in combination with programmed cell death ...
UPCC 31923: A Phase 1 Study with ABBV-CLS-484
Clinical Studies for Medical Research , UPCC 31923: A Phase 1 Study with ABBV-CLS-484 Alone and in Combination in Subjects with Locally ...
Clinical Trial: NCT04777994 - My Cancer Genome
... 484 as monotherapy and in combination with a PD-1 targeting agent. ... Part 3, ABBV-CLS-484 will be administered alone as a monotherapy at ...
First-in-human phase 1 studies of PTPN2/1 inhibitors ABBV-CLS ...
In both ESC and EXP phases, the study drug (ABBV-CLS-484 or ABBV-CLS-579) is administered orally either alone or in combination with ...
A Phase 1 Study With ABBV-CLS-484 in Subjects With Locally ...
The study will assess the safety, PK, PD, and preliminary efficacy of ABBV-CLS-484 as monotherapy and in combination with a PD-1 targeting ...
Advanced Renal Cell Carcinoma Clinical Trials - NCI
The study will assess the safety, PK, PD, and preliminary efficacy of ABBV-CLS-484 as monotherapy and in combination with a PD-1 targeting agent or with a or a ...
Kidney Cancer Clinical Trials - Rogel Cancer Center
A Phase 1 Study with ABBV-CLS-484 Alone and in Combination in Subjects with Locally Advanced or Metastatic Tumors (I) Primary Investigator: Vaishampayan ...
Solid Tumors - clinical trials search - AbbVie Science
... Study With ABBV-CLS-484 Alone and in Combination in Subjects With Locally Advanced or Metastatic Tumors. ABBV-CLS-579. M20-124: A Phase 1, Multi-center, Open ...
Lung Cancer Clinical Trials - Rogel Cancer Center
A Phase 1 Study with ABBV-CLS-484 Alone and in Combination in Subjects with Locally Advanced or Metastatic Tumors (I) Primary Investigator: Vaishampayan ...
Nature Publishes Discovery and Preclinical Results for ABBV-CLS ...
Through in vivo studies and single cell transcriptional profiling ... Phase 1 clinical trial in solid tumors (NCT04777994). "This is an ...
Abstract ND06: ABBV-CLS-484: An active site PTPN2/N1 inhibitor ...
Based on these robust preclinical data, phase I clinical trials of ABBV-CLS-484 alone and in combination with an anti-PD-1 agent have been ...
A Phase 1, Multi-center, Open Label First-in-Human ... - MediFind
... Study With ABBV-CLS-484 Alone and in Combination in Subjects With Locally Advanced or Metastatic Tumors. Who is this study for? Patients with Advanced Solid ...
A phase 1 study of the pan-bromodomain and extraterminal inhibitor ...
A phase 1 study of the pan-bromodomain and extraterminal inhibitor mivebresib (ABBV-075) alone or in combination with venetoclax in patients ...
AbbVie Showcases Advancement of Solid Tumor Pipeline at ESMO ...
New safety and efficacy data from a Phase 1 study (NCT05029882) of ABBV-400, a next-generation, potential best-in-class c-Met directed ADC ...
770 Safety, efficacy, and pharmacokinetic results from a phase I first ...
Acknowledgements AbbVie and the authors thank all the trial investigators and the patients who participated in this clinical trial. Medical writing support was ...
A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation ...
ABBV-383, a B-cell maturation antigen × CD3 T-cell engaging bispecific antibody, has demonstrated promising results in an ongoing first-in-human phase I study.